Tag
Nandini Piramal
2 articles
Piramal Pharma Q4 Revenue Flat, FY26 PAT at -₹326Cr
Piramal Pharma reported flat Q4 revenue of ₹2,752Cr, with a full-year decline of 3% to ₹8,869Cr, impacted by CDMO destocking and soft ex-US anesthesia sales.
The company recorded a full-year net loss
Piramal Pharma Q4 Net Profit Dips 5.6% YoY
• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting FY net profit of ₹700.01 crore.
• Reappointed four directors including Executive Ch